Wyeth received marketing authorization from the European Commission for Conbriza (bazedoxifene), a selective estrogen receptor modulator (SERM), for the treatment of postmenopausal osteoporosis in women at increased risk of fracture.

“Analyses of clinical trial data showed that treatment with Conbriza significantly decreased the risk of all clinical fractures and non-vertebral fractures for women who were at a greater risk of osteoporotic fracture,” says Gary L. Stiles, M.D., executive vice president, chief medical officer, Wyeth Pharmaceuticals. “Importantly, the analyses also showed that the higher a woman’s risk of a fracture, the greater the protection she received with Conbriza therapy.”

Wyeth plans to introduce the drug in certain European markets after receiving the necessary reimbursement authorizations in those markets. Wyeth is also seeking regulatory approval of bazedoxifene for the prevention and treatment of postmenopausal osteoporosis in the U.S. and other countries.